Position in ERAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,174,881
+$4,393,216 QoQ
Shares Held
391,642
+127.8% QoQ
Ownership
0.112%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#69
of 257 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cinctive Capital Management LP holds $200,361,017 across 44 Biotechnology names. ERAS ranks #7 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
350,165 | $46,477,400 | |
| 2 | INSM |
INSMED Inc
|
161,996 | $17,272,013 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,712 | $13,268,651 | |
| 4 | CYTK |
Cytokinetics Inc
|
137,838 | $11,742,419 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
226,140 | $8,003,094 | |
| 6 | NTHI |
Neonc Technologies Holdings, Inc.
|
1,607,464 | $7,281,811 | |
| 7 | ERAS |
Erasca, Inc.
This page
|
391,642 | $7,174,881 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
16,367 | $6,083,122 |
All Filings in ERAS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,174,881 | 391,642 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,781,665 | 171,920 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||